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ABSTRACT  
Preparation of surface modified Embelin loaded nanoparticles (GA-PEG-PLGA) for the management of hepatotoxicity. Surface modified Embelin 
loaded GA-PEG-PLGA NPs were evaluated by NMR, FTIR, TEM techniques and in vitro release studies. The biodistribution of the nanoparticles 
was assessed by High-performance liquid chromatography (HPLC), and the cellular uptake study was evaluated using Hep G2 cells (liver cells 
lines). The hepatoprotecttive effect of the surface modified Embelin loaded GA-PEG-PLGA NPs was investigated in-vitro and in-vivo. The surface 
modified Embelin loaded GA-PEG-PLGA nanoparticles significantly increases the uptake of drug in liver by 2.5 folds more than plain drug.  
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1. INTRODUCTION 
Liver, the largest gland of the body, is a vital organ. It is an 
important and complex organ, located in the right upper 
quadrant of abdomen. Its functions including detoxification 
of chemicals, metabolism of drugs, protein synthesis, and the 
production of biological chemicals, are necessary for the 
conservation of life. Thus, the patients with long term liver 
diseases such as hepatitis, liver fibrosis, and hepatic cancer 
need immediate attention to sustain life, and as a result are 
often exposed to the prolonged treatment with drugs (1). But 
the liver is the site for drug detoxification and 
biotransformation of exogenous chemicals that penetrate 
body systems via distinct routes (2). Therefore it is very 
important to seek new therapeutic strategies to treat liver 
diseases. Targeted drug delivery, which can carry the drugs 
to specific organs or tissues, is a highly desirable strategy to 
improve the therapeutic outcome, with significantly 
decreased toxic side-effects compared to traditional 
chemotherapy (3, 4). It is the metabolic “engine room of the 
body”. Embelin (2, 5-dihydroxy-3-undecyl-1, 4 - 
benzoquinone) is a naturally occurring alkyl benzoquinone, 
the active principle in the fruits of Embelia ribes belonging to 
family Myrsinaceae. Embelin have been reported for the 
treatment of various liver diseases like jaundice (5, 6). 
Embelin protects the liver injury caused by alcohol 
administration. In view of its nontoxic nature, it may be 
developed as an effective therapeutic agent for alcohol-
induced liver disease by its antioxidant and anti-
inflammatory features (7, 8). Accumulated evidence has 
demonstrated that both oxidative stress and abnormal 
cytokine production, especially tumor necrosis factor-α 
(TNF), play important etiological roles in the pathogenesis of 
alcoholic liver disease (ALD). Agents that have both 
antioxidant and anti-inflammation properties, particularly 
anti-TNF production, represent promising therapeutic 
interventions for ALD (5, 9). We investigated the effects and 
the possible mechanism of Embelin on liver injury induced 
by alcohol administration. 
Abundantly available receptor, which is specific to hepatic 
parenchymal cells is asialoglycoprotein receptor. It has the 
ability to recognize the galactosylated ligands, lactobionic 
acid ligand, asialofetuin ligands, soybean derived 
steryglyucoside (SG) ligands and many more. Similarly, 
glycyrrhetinic acid receptors are mainly found on the 
sinusiodal surface of mammalian hepatocytes. It has ability 
to recognize the glycyrrrhetinic acid ligands (10). 
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Glycyrrhetinic acid (GA) is a hydrolysis product of 
glycyrrhizic acid (GL), which is the main component of the 
Traditional Chinese Medicine liquorice. It was reported that 
there are some highly specific GA binding sites located on the 
surface of liver parenchyma cells (11).The investigations of 
GA-mediated targeted drug delivery systems such as 
liposomes, nanoparticles and polymeric micelles have 
become more and more popular. Wei Huang was prepared 
nanoparticles of paclitaxel by using glycyrrhetinic acid as 
targeting ligand and hyalouronic acid as polymer (12). 
Prepared nanoparticles showed high efficiency upto 31.16% 
and entrapment efficiency of 92.02%. The prepared 
conjugate showed high liver targeting as compared to the 
other organs. Hiraku Onishi was prepared Poly (L-lactic acid-
co-glycolic acid) with glycyrrhetic acid-containing 
microparticles as dosage forms for liver-specific delivery of a 
liver-protective drug (13). Zhi Yuan was prepared 
nanoparticles with PLGA and Glycyrrhetinic acid-mediated 
nanoparticles of hepatic targeted drug delivery system (14). 
In our study, Embelin is formulated as a hepatoprotective 
agent for liver targeting. Aim of the present study was to 
design surface modified PLGA nanoparticles combined with 
an active ligand (GA) to achieve the desired targeting 
performance. The main aim of the study is to make embelin 
loaded glycyrrhetinic acid modified PLGA nanoparticles as 
novel hepatic drug delivery system and prepared 
formulation was further evaluated for serum glutamic 
oxaloacetic transaminase (SGOT) and serum glutamic 
pyruvic transaminase (SGPT), alkaline phosphate (ALP) and 
total bilirubin (TB) assessment of liver function. 
2. MATERIALS & METHODS 
PLGA (MW 8000 Da, Copolymer ratio 50:50) and Bis amine 
PEG were obtained from Sigma-Aldrich, Dialysis membrane 
(MWCO 5, 10, 12 and 14 KD) were purchased from Himedia 
labs, (India). Glycyrrhetinic Acid, Dicyclohexylcarbodiimide 
(DCC) and N-hydroxy-succinimide (NHS) were obtained from 
Himedia Pvt Ltd, Embelin was obtained from Indofine 
chemical company, Inc, USA and Hep G2 cell lines were 
obtained from National Centre for Cell Sciences (NCCS). All 
other chemicals were used of extra pure grade. 
2.1 Synthesis of Glycyrrhetinic Acid -PEG-PLGA 
Conjugate 
The GA-PEG-PLGA conjugate was synthesized in four steps, 
i.e. glycyrrhetinic acid (GA) activation, PLGA activation, 
synthesis of GA-PEG-NH2, and final synthesis of GA-PEG- 
PLGA conjugate as depicted in Fig 1. 
 
 
Figure 1. Final synthesis of GA-PEG- PLGA conjugate 
 
Activation of Glycyrrhetinic Acid (GA) 
Activation of glycyrrhetinic acid was performed according to 
the method described by Yogesh B. Patil with few 
modification, glycyrrhetinic acid (2.0 g) was dissolved in a 
mixture of anhydrous chloroform (80 ml) and triethylamine 
(TEA 1.0 ml), and it was stirred for overnight in dark (15). 
Then, the resultant solution was further stirred for 18 hrs, 
after mixing of dicyclohexylcarbodimide (DCC 1.0 g) and N-
hydroxysuccinamide (NHS, 0.56 g) in it. Finally, side product 
dicyclohexylurea (DCU) was removed by filtration and 
solvents like chloroform and TEA were evaporated under 
vacuum. 
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Activation of PLGA Polymer 
Activation of PLGA (average molecular weight of 8000 Da) 
was carried out according to the method described by 
Haizheng Zhao briefly, 2 g of PLGA was activated by DCC 
(56.5 mg) and NHS (31.5 mg) (molar ratio 1:1.1:1.1, 
respectively) in 5 ml of dichloromethane (DCM) at room 
temperature under nitrogen gas for 24 h (16). The resultant 
was filtered to remove the by product dicyclohexylurea 
(DCU). After filtration, activated PLGA was precipitated by 
ice-cold diethyl ether and dried under vacuum. 
Preparation of GA-PEG-NH2 
Glycyrrhetinic acid was conjugated with bis amine PEG (NH2- 
PEG-NH2) according to the method described by Yogesh B. 
Patil with slight modifications, Bis-amine-PEG 2.0 g (150 
times more than NHS- GA acid, average molecular weight of 
4000 Da) was dissolved in acetonitrile (4.0 ml) (15). 
Methylene chloride (2.0 ml) and TEA (1.6 ml) were added to 
the above mixture and the solution was stirred for 1 min 
only. NHS- GA (500 mg) was added to the above mixture and 
stirred overnight under nitrogen. The reaction was blocked 
by the dropwise addition of diethyl ether (10-15 ml) to 
precipitate the polymer and separate the unreacted PEG. 
Then precipitated polymer was filtered and washed with 
diethyl ether. The untreated polymers were separated by 
dialysis (dialysis membrane MWCO, 4000).  
Synthesis of GA-PEG- PLGA conjugate copolymer 
The final synthesis was performed according to the method 
described by Haizheng Zhao with few modifications (16). 
Activated PLGA (1.0 g) and GA-PEG-NH2 (1.2 g) were added 
to 5 ml of chloroform at room temperature for 8 hrs under 
nitrogen gas. Then final product was precipitated in ice cold 
diethyl ether, and then this was further dissolved in 
chloroform and dialyzed for the removal of chloroform and 
unreacted polymers against deionized water over 72 hrs 
(MWCO 12000). The further collected copolymer (GA-PEG-
PLGA) was dialyzed in chloroform (MWCO 14000) to remove 
the PLGA-PEG-PLGA copolymers. Then, the dialyzed 
copolymers were obtained by dialysis membrane against 
deionized water over 72 hrs, and also from vacuum dryer. 
Finally these were lyophilized, and final product was 
analyzed for conjugation through NMR spectrum. The 
conjugate was dissolved in CDCI3 and 1H NMR spectra was 
recorded with employing NMR Spectrometer. 
2.2 Preparation of Polymeric Conjugate (GA-PEG-PLGA) 
Nanoparticles by Nanoprecipitation Method 
PLGA (50:50) nanoparticles are usually prepared by 
nanoprecipitation method. Nanoparticles were prepared 
according to the literature (17), with some modifications. 
GA-PEG-PLGA nanoparticles were formed spontaneously 
upon addition of various concentrations of GA-PEG-PLGA 
(0.5, 1, 1.5, 2, 2.5 and 20.0 mg/ml) and homogenization 
under varying time and speed. Embelin-loaded nanoparticles 
were formed by incorporation of the solution into the GA-
PEG-PLGA solution containing 0.5 mg/ml embelin at the 
same ratio (15, 18). The solutions were stirred for 2 hours, 
followed by the complete removal of all organic solvents on 
the rotary evaporator. The nanoparticles are obtained as 
dispersed in the water solution (19, 20).  
3. Characterization of Nanoparticles 
3.1 Particle Size Analysis 
Particle size and size distribution was determined by photon 
correlation spectroscopy using a Zeta sizer (Beckman 
Coulter Pvt. Ltd.). A dilute suspension of NPs (20μg/ml) was 
prepared in deionized distilled water and measurements 
were taken in specific disposable cuvettes and recorded. 
3.2 Surface Morphology (TEM)  
The transmission electron microscopy of the Embelin loaded 
polymeric nanoparticles was analyzed by the transmittance 
electron microscopy by using the stain phosphotungstic acid. 
TEM is a method of probing the microstructure of rather 
delicate system such as micelles, liquid crystalline phases, 
vesicles, emulsions and also nanoparticles. A drop of particle 
dispersion was spread onto a 200 mesh copper grid coating 
and the droplets excess was removed with a filter paper. 
After 5 min, a drop of 2% phosphotungstic acid was placed 
onto the copper grid. The grid was dried at room 
temperature and observed by TEM. 
3.3 Entrapment Efficiency 
The entrapment efficiency of the Embelin loaded surface 
modified polymeric nanoparticles was carried out by 
centrifugation at low temperature and taking the absorption 
of supernatant at UV spectrophotometer at 292 nm. The 
formula used for the calculation of the entrapment efficiency 
is given as:  
 
3.4  In-vitro Drug Release Studies 
In vitro drug release profile of entrapped drug from 
nanoparticles was studied at two different pH (1.2 and 6.8) 
using dialysis bag. In order to mimic gastric and intestinal 
environment the release of Embelin from Embelin loaded 
GA-PEG-PLGA nanoparticles were observed at SGF (pH 1.2) 
and SIF (pH 6.8), respectively. Dialysis membrane was 
exposed to running water for 12 hours. In-vitro drug release 
studies were performed by dialysis bag method at rotation 
speed of 100 rpm. Acidic buffer solution (pH 1.2) was used as 
dissolution medium. Each dialysis bag (pore size: 12KD, 
Sigma Chemical Co., USA) was loaded with 20 mg 
nanoparticles. Volume and temperature of dissolution 
medium were 200 ml, and37.0± 0.2 oC respectively. At 
predetermined time interval, samples (5ml) were withdrawn 
and replaced with same volume of fresh media for duration 
of 2 hours. The same procedure was repeated with basic 
buffer solution pH 6.8 for a time period of 120 hours along 
with sample withdrawal and replacement at predetermine 
time interval, filtered and assayed for drug content at 292 
nm against blank using UV-Visible spectrophotometer. 
3.5 In-vivo Studies 
The formulation is prepared in order to target the drug 
directly to the liver. To investigate the beneficial potential of 
the final formulation (F12) in a hepatotoxicity experimental 
study in wistar rats was carried out. Wistar rats weighing 
180-220 g of either sex were used. Animals were obtained 
from Central Animal House Facility of I.S.F. College of 
Pharmacy, Moga, Punjab, India. They were housed at ambient 
temperature (21±10°C) and relative humidity (55 ± 5%) 
with fixed 12h light/dark cycle. The experimental protocol 
was approved as ISFCP/IAEC/CPCSEA/2015/265 by 
Institutional Animal Ethical Committee (IAEC) as per the 
guidance of committee for the purpose of control and 
supervision of experiments on animals (CPCSEA). 
Hepatotoxicity was induced by administration of 40% 
alcohol at dose of 2 ml/100 g/day, p.o. for 21 days. Standard 
(Silymarin 25 mg/kg., p.o), Embelin (25 mg/kg., p.o) and GA-
PEG-PLGA loaded Embelin (25 mg/kg., p.o) were suspended 
in 0.5% CMC (Carboxyl methylcellulose) solution and 
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administered per orally for 21 days in respective groups, one 
and half hour prior to alcohol dosing. On 21st day all animals 
were sacrificed, blood was collected for assessment of liver 
function (SGOT, SGPT, ALP, and TB). The rats were divided 
into five different groups (n=5) as shown in Table 1. 
  
Table 1. Optimization of polymer conjugate concentration 
Formulation Conjugate conc  
(w/v) 
Homoginization Time  
(min) 
Homoginization speed  
(rpm) 
Particle Size 
(nm) 
PDI 
F1 0.5% 10 4000 223.3±1.1 0.188 
F2 1% 10 4000 291±1.4 0.261 
F3 1.5% 10 4000 355.1±1.2 0.209 
F4 2% 10 4000 438.2±0.9 0.192 
F5 2.5% 10 4000 495.2±0.8 0.267 
F6 3% 10 4000 571.3±1.3 0.241 
Number of groups = 5; Total no. of rats = 25 (5 Rats in each group); Dose = 25mg/kg/ per oral 
 
3.6 Hepatotoxicity Study of Final Polymeric Conjugate & 
Optimized Drug Loaded Nanoparticulate Formulation. 
Since the formulation is prepared in order to target the drug 
(Embelin) directly to the liver, Hence it becomes very 
important to check the hepatotoxicity of the final prepared 
polymeric conjugate as well as the drug loaded final 
nanoparticulate formulation. Different tests like 
determination of SGOT, SGPT and ALP and TB level study of 
the liver were done in order to check the liver toxicity of the 
final polymeric conjugate and final nanoparticulate 
formulation. 
3.6.1 Aspartate transaminase (AST/SGOT) 
Oral administration of 40% alcohol (2 ml/100 g) treatment 
caused a significant increased SGOT level. AST (SGOT) 
catalyses the transfer of amino group between L-Aspartate 
and α- Ketoglutarate to form oxaloacetate and glutamate. 
The oxaloacetate formed reacts with NADH in the presence 
of malate dehydrogenase to form NAD. The rate of oxidation 
of NADH to NAD is measured as a decrease in absorbance is 
proportional to the AST (21). The surface modified Embelin 
GA-PEG-PLGA NPs protect the liver and reduce the increase 
level of the SGOT in the liver enzyme. 
3.6.2 Alanine transaminase (ALT/ SGPT) 
Oral administration of 40% alcohol (2 ml/100 g) treatment 
caused a significant increased SGPT level. ALT (SGPT) 
catalyses the transfer of amino group between L-alanine and 
α- ketoglutarate to form pyruvate and glutamate. The 
pyruvate formed reacts with NADH in the presence of lactate 
dehydrogenase to form NAD. The rate of oxidation of NADH 
to NAD is measured as a decrease in absorbance which is 
proportional to the ALT (21). The surface modified Embelin 
GA-PEG-PLGA NPs protect the liver and reduce the increase 
level of the SGPT in the liver enzyme. 
3.6.3 Alkaline phosphatase (ALP) 
Oral administration of 40% alcohol (2 ml/100 g) treatment 
caused a significant increased ALP level. ALP in an alkaline 
pH, hydrolyses p-nitrophenylphosphate to form p-
nitrophenol and phosphate; the rate of formation of p-
nitrophenol is measured as an increase in absorbance which 
is proportional to the ALP activity in the sample (22). The 
surface modified Embelin GA-PEG-PLGA NPs protect the 
liver and reduce the increase level of the ALP in the liver 
enzyme. 
3.6.4 Total bilirubin level (TB) 
Oral administration of 40% alcohol (2 ml/100 g) treatment 
caused a significant increased TB   level. Bilirubin reacts with 
diazotized sulphanilic acid to form a coloured azobilirubin 
compound. The unconjugated bilirubin couples with the 
sulphanilic acid in the presence of a caffeine-benzoate 
accelerator. The intensity of the colour formed is directly 
proportional to the amount of bilirubin present in the 
sample (23). Embelin GA-PEG-PLGA NPs protect the liver 
and reduce the increase level of the TB in the liver enzyme. 
3.7 Cellular Uptake Study  
Cell uptake study of the formulation was performed for 
qualitative estimation of the uptake of drug by the liver cells. 
Cell uptake study of Embelin drug loaded surface modified 
(PLGA-PEG-GA) conjugated nanoparticles was performed on 
HepG2 cells by using rhodamine dye (Fluorecent dye) [20]. 
The cell culture was freshly prepared by sub culturing the 
cells using Dulbecco’s Minimum Essential Medium (DMEM). 
Formulation was incubated with the cells using 6 well 
culture plates for 2 hours. Plain cells in media served as 
positive control. Images of control and test sample were 
taken using Fluoroscent Microscope (Olympus, CK X 41). 
3.7 In-vivo Pharmacokinetic and Liver Homgenate 
Studies Bioanalytical Method Development by HPLC for 
Pharmacokinetic Studies 
Optimized analytical method was already developed which 
is a selective and sensitive method for analysis of Embelin on 
HPLC using UV detection by PDA (Photo diode array) 
detector. A mobile phase of potassium dihydrogen 
orthophosphate (KH2PO4) buffer of pH 7.4 was investigated 
to develop a fully validated assay method using UV 
detection. The full validation of this method was performed 
on an HPLC-PDA system. 
4. RESULTS AND DISCUSSION 
4.1 Optimization of Embelin loaded polymeric 
conjugated nanoparticles 
The prepared formulations were evaluated to get an 
optimized formulation. The different parameters were 
optimized such as polymer drug concentration, 
homogenization time and speed. Particle size is the most 
important parameter for target drug delivery. Smaller sized 
particles have larger surface area. The formulation was 
optimized according to their particle size, and polydispersity 
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index. The optimization of finally prepared polymeric 
conjugated   nanoparticles is optimized upto F1 to F6, 
however F1 is optimized polymeric conjugated   
concentration and which is shown in Table 2. As we increase 
the polymer concentration the particle size of nanoparticles 
increases, it may be because of increase in the uniform 
coating of polymer solution over the nanoparticle systems. It 
was seen that after certain limit with the increase in the 
homogenization time and speed the size of nanoparticles 
increases this is because of the increase in the kinetic energy 
of the nanoparticles leading to aggregation in particles. The 
time and speed in homogenization are optimized in 
formulation F7 to F10 and the optimized formulation is F9 
which is shown in Table 2. The optimization of drug 
concentrations were evaluated for entrapment efficiency 
and the formulation with maximum efficiency was selected 
as the final formulation (F9) is given in the Table 2. It was 
seen that with the increase in drug concentration the 
entrapment efficiency of nanoparticles increase till the ratio 
of polymer and drug was 2:1. With further increase in the 
drug concentration the size of nanoparticles increases and 
entrapment efficiency decreases and the final optimized 
formulation is F12. 
 
Table 2: Optimization of Homoginization Time (min) 
Formulation Conjugate conc 
(w/v) 
Homoginization Time 
(min) 
Homoginization speed 
(rpm) 
Particle Size 
(nm) 
PDI 
F7 0.5% 10 4000 442.5±1.7 0.207 
F8 0.5% 15 4000 338.2±1.6 0.250 
F9 0.5% 20 4000 212.9±1.1 0.132 
F10 0.5% 25 4000 378.1±1.6 0.175 
 
4.2 Characterization of optimized formulation of GA-
PEG-PLGA Nanoparticles 
Surface modified (GA-PEG-PLGA) NPs were prepared by the 
nanoprecipitation method (15, 24). The copolymer (GA-PEG-
PLGA) was synthesized and the final product of copolymer 
confirmed by 1H NMR spectroscopy results. The 1H NMR 
spectrum (Figure 2) shows proton peaks at 3.5 ppm for NH2 
and NH, and ~1.0 ppm for CH2 which confirms presence of 
PEG, and hydrogen of the methine group of the lactic acid 
unit of the PLGA copolymer resonated at 5.3 ppm, whereas 
those of the methylene group of the glycolic acid unit 
appeared at 4.8 ppm and ~1.5 ppm of CH3 confirms presence 
of PLGA. The peaks shown in the Figure 2, also matched with 
the peaks of PEG and PLGA as described by Yadav, Zhao and 
Patil (15, 16, 25). In Figure-2 the additional proton peaks at 
6.80 and 7.21 ppm exhibit the presence of C-NH, and 1-
benzene CH, respectively which confirm the presence of GA-
PEG, whereas other proton peaks were same as Figure 3 
which confirms the presence of PEG and PLGA. The peaks 
shown in the Figure 3, also matched with the peaks of PLGA, 
PEG and GA as described by Zhao and Patil (15, 16). So it can 
be concluded that both the conjugation has been successfully 
developed. These prepared surface modified GA-PEG-PLGA 
NPs were characterized for shape and surface morphology, 
particle size, drug entrapment efficiency. The GA-PEG-PLGA 
NPs were obtained in an average size of 316±1.9 nm with an 
entrapment efficiency of 96.3±3.1 % and the particle size 
was analyzed by Zeta sizer. 
 
 
Figure 2. 1H NMR spectrum synthesis of GA-PEG- PLGA conjugate 
The optimized formulation was visualized under 
transmission electron microscopy (TEM). Figure 3 shows 
TEM images of optimized NPs. TEM images revealed that NPs 
formed were small in size and were almost spherical in 
shape. The TEM photomicrograph exhibits NPs indicating 
that optimized formulation of GA-PEG-PLGA nanoparticles 
initially confirms burst release and 80±4.5 % drug release in 
120 h. This could also be due to complete hindrance of core 
through PEG over the surface of NPs. Finally more sustained 
release of drug from GA-PEG-PLGA NPs also increases the 
effectiveness of carrier for the treatment of hepatotoxicity. 
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Figure 3. TEM images of embelin loaded GA-PEG- PLGA 
NPs. 
      4.3 In-vitro Drug Release Studies 
In-vitro drug release was performed using dialysis bag at pH 
1.2 and 6.8. In order to mimic the conditions of our system, 
the release study is performed at gastric pH (SGF pH 1.2) and 
intestinal pH (SIF pH 6.8) separately. Figure 4 shows the in 
vitro drug release from surface modified (PLGA-PEG-GA) 
NPs. In-vitro cumulative release was carried out for 
optimized formulation ((PLGA-PEG-GA) nanoparticles) using 
Embelin at pH 1.2 and 6.8 and it was observed that the drug 
release was found to be 6.04 % for 2 hours at SGF (pH 1.2) 
and was 80±4.5% at SIF pH 6.8 as compare to pH 1.2. In-vitro 
release profile establishes the enteric coating of the prepared 
formulation. Polyanionic nature of the polymer remains 
nonprotonated in the gastric pH. Thereby inhibits the release 
of encapsulated therapeutics whereas intestinal pH induces 
the protonation of the coating material causes a controlled 
release of encapsulated material. Controlled release is 
further attributed to the physiochemical behaviour of 
polymer conjugate where the conjugate remains 
unprotonated in intestinal pH, thus restrict the free access to 
dissolution medium, leads to controlled diffiusion of drug.
 
 
Figure 4. In- vitro drug release simulated gastric fluid 1.2 and PBS 7.4 
 
4.4 Cellular Uptake Study  
Cell uptake studies of the formulation were performed for 
the qualitative estimation of uptake of the nanoparticles by 
liver cells. Image of the cells taken after 12 hours of 
incubation with dispersion of drug loaded nanoparticles is 
shown in Figure 5. 
 
 
Figure 5. Representation of the Cellular uptake (a) plain Embelin (b) standard drug Silymarin (c) Embelin loaded GA-
PEG-PLGA NPs. 
It is clearly revealed from the images that the surface 
modified Embelin loaded (GA-PEG-PLGA) NPs has the 
maximum cellular uptake as compared to plain drug have 
less cellular uptake in comparisons. A high cellular uptake of 
polymer conjugated nanoparticles established the proposed 
hypothesis. In that the presence of GA improves the cellular 
efficiency of developed formulation for hepatic cells. Cell 
uptake study further confirms that receptor mediated 
endocytosis is a key mechanism for cellular uptake of 
developed formulation. 
4.5 In-vivo Drug Concentration 
HPLC method was developed in human plasma for 
estimation of Embelin. Plasma drug concentration-time 
profile of surface modified Embelin loaded GA-PEG-PLGA 
nanoparticles (F12), administered orally in wistar rats is 
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present in Table 3 represents various pharmacokinetic 
parameters. From the given results it was observed that the 
developed optimized formulation showed increased plasma 
concentration (61.49 µg/ml) and T1/2 (41.44 hrs) than the 
plain drug and significant to the standard drug. Further the 
plasma concentration takes longer time to reach its 
maximum value in case of F12 formulation followed by plain 
drug showing sustained release in case of GA-PEG-PLGA 
formulation. This could be attributed to preferential 
localization of polymer conjugate nanoparticle in liver. 
Polymer conjugate showed 25 % rise in Cmax value which 
could be attributed to increase bioavailability of developed 
formulation attributed to nanoparticles dispersion, 
controlled release mechanism and retention of the 
developed formulation near the absorption window. Further 
a higher Tmax in developed formulation is associated with its 
high affinity for hepatic cell lines. Further a higher Tmax in 
developed formulation is associated with its high affinity for 
hepatic cell lines. 
  
Table 3. Plasma pharmacokinetic parameters of different formulation 
Parameters Silymarin Glycyrrhetinic  acid  –PEG-PLGA 
Embelin nanoparticles 
Plain drug solution 
Cmax (µg/ml) 63.23 61.49 43.55 
Tmax (hour) 32 32 24 
T1/2 (hour) 46.58 41.44 19.5 
AUC total (µg/ml) 5896.5 5430.1 2764 
MRT 77.72 71.93 50.59 
 
Further the localization of receptor along the sinusoid cell 
lines improves hepatic permeability and retention of the 
developed formulation in the liver as shown in Table 4. For 
this all animals were sacrificed on 21st day under light ether 
anesthesia; blood samples were collected and allowed to clot 
for 30 minutes at room temperature, then centrifuged at 
3000 rpm for 20 minutes. Serum was separated and stored 
at -20°C until biochemical estimation for liver profile. 
  
Table 4. Represents amount of drug in liver with respect to time 
Time (hour) Silymarin 
(μg/ml) 
GA-PEG-PLGA 
(μg/ml) 
Plain drug  solution 
(μg/ml) 16 42.26±2.34 40.24±2.81 15.87±2.1 
32 63.38±2.78 61.43±2.45 28.09±2.37 
72 30.51±2.9 28.03±2.31 12.87±2.04 
120 16.05±2.76 14.24±2.21 4.34±2.43 
 
Figure 6 (a) depicts graphical representation of plasma 
concentration of Embelin at each time interval point which 
indicates that highest plasma concentration of Embelin at 
each time interval point which indicates that highest plasma 
concentration was obtained from F12 nanoparticles 
formulation which is comparable and significant to 
marketed Silymarin (p<0.05). From Figure 6 (b) it is 
concluded that the amount of drug uptake in the liver is 
more in GA-PEG-PLGA nanoparticles as compared to plain 
drug and significant to the standard drug Silymarin (p<0.05). 
The final formulation F12 nanoparticles increase the 
bioavailability of drug in liver by 2.0 folds more than plain 
drug. So it can be attributed that Glycyrrhetinic acid has the 
ligand properties for the receptors presents in the liver, so 
can be used for liver targeting, as well as it is efficient 
against hepatotoxicity. 
 
 
Figure 6. Representation of the (a) plasma concentration of Embelin (b) Embelin concentration in liver  
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4.6 Hepatotoxicity Study of Final Formulation 
Effect of surface modified (GA-PEG-PLGA) Embelin loaded 
nanoparticles was studied on liver enzymes such as Serum 
glutamic oxaloacetic transaminase (SGOT), Serum glutamic 
pyruvic transaminase (SGPT), Total bilirubin (TB) and 
Alkaline phosphatase (ALP) in 40% alcohol induced rats 
suffering from hepatotoxicity. Oral administration of 40% 
alcohol (2 ml/100g) treatment caused a significant increase 
liver enzymes level on 21st day as compared to control 
treated group. Treatment with standard drug silymarin (25 
mg/kg), plain Embelin (25mg/kg), surface modified (GA-
PEG-PLGA) nanoparticles (25 mg/kg) showed significant 
decrease in liver enzymes level as compared to 40% alcohol 
treated group. However effect of surface modified Embelin 
loaded GA-PEG-PLGA NPs was more significant in 
comparison to Plain Embelin, that may be due to selective 
ligand targeting of Embelin loaded GA-PEG-PLGA NPs to the 
liver which is shown in Figure 7a - 7d, so that it can be used 
for liver targeting, as well as it is efficient against 
hepatotoxicity.
 
 
Figure 7. Effect of Embelin and Embelin loaded (GA-PEG-PLGA) NPs in alcohol induced change in (a) SGOT  (b) SGPT (c) 
ALP (d) TB 
 
5. CONCLUSION  
This work report that GA-PEG-PLGA nanoparticles can be 
used as the carrier of Embelin for hepatotoxicity for liver 
targeting in effective management of alcohol induced 
hepatotoxicity. Liver targeted nanoparticles (GA-PEG-PLGA) 
composed of GA and PLGA could be prepared conveniently 
by the nanoprecipitation method. GA-PEG-PLGA NPs are 
nearly spherical of 316 nm in diameter with homogeneous 
structure and smooth surfaces. A significant decline in the 
percent drug release of Embelin from GA-PEG-PLGA NPs SIF 
(pH 6.8) indicated that coupling of glycyrrhetinic acid slows 
down the release of drug from the NPs and thereby imparts 
a sustained release nature. When Embelin given by oral 
route, blood circulation distributed it to all the organs, this is 
remarkably higher than that of the nanoparticles with the GA 
in liver. Moreover, the in vitro cell uptake results showed 
that the introduction of GA to the nanoparticles could 
significantly increase the affinity to hepatictoxicity with 
approximately an improvement in cellular uptake. Surface 
modified Embelin loaded (GA-PEG-PLGA) NPs significantly 
reduced the levels of SGOT, SGPT, ALP and TB in comparison 
to Alcholic-Hepatotoxic group rats. More significant 
improvement in liver function by Surface modified Embelin 
loaded (GA-PEG-PLGA) NPs in comparison to plain embelin 
may be attributed to increase in targeting of liver due to 
interaction of GA with its liver GA- receptors. Thus it is 
concluded that surface modification of embelin loaded (GA-
PEG-PLGA) NPs increases the liver targeting and have 
beneficial potential in alcoholic induced hepatoxocity. 
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